Who are TACE+Camrelizumab+Apatinib mesylate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tace-camrelizumab-apatinib-mesylate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

TACE+Camrelizumab+Apatinib mesylate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TACE+Camrelizumab+Apatinib mesylate (TACE+Camrelizumab+Apatinib mesylate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: locoregional chemotherapy + PD-1 inhibitor + tyrosine kinase inhibitor. Area: Oncology.

phase 3 Combination therapy: locoregional chemotherapy + PD-1 inhibitor + tyrosine kinase inhibitor PD-1 (camrelizumab); VEGFR, c-Kit, RET, FLT3 (apatinib mesylate); TACE is procedural Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TACE+Camrelizumab+Apatinib mesylate (TACE+Camrelizumab+Apatinib mesylate) — Jiangsu HengRui Medicine Co., Ltd.. This combination therapy uses transarterial chemoembolization (TACE) to deliver chemotherapy directly to liver tumors, combined with camrelizumab (a PD-1 inhibitor) to enhance immune response and apatinib mesylate (a tyrosine kinase inhibitor) to block angiogenesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TACE+Camrelizumab+Apatinib mesylate TARGET	TACE+Camrelizumab+Apatinib mesylate	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Combination therapy: locoregional chemotherapy + PD-1 inhibitor + tyrosine kinase inhibitor	PD-1 (camrelizumab); VEGFR, c-Kit, RET, FLT3 (apatinib mesylate); TACE is procedural

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: locoregional chemotherapy + PD-1 inhibitor + tyrosine kinase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TACE+Camrelizumab+Apatinib mesylate — Competitive Intelligence Brief. https://druglandscape.com/ci/tace-camrelizumab-apatinib-mesylate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab